MX2015015194A - Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales. - Google Patents
Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales.Info
- Publication number
- MX2015015194A MX2015015194A MX2015015194A MX2015015194A MX2015015194A MX 2015015194 A MX2015015194 A MX 2015015194A MX 2015015194 A MX2015015194 A MX 2015015194A MX 2015015194 A MX2015015194 A MX 2015015194A MX 2015015194 A MX2015015194 A MX 2015015194A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- disease
- cranial nerves
- anesthesia
- auricular anesthesia
- Prior art date
Links
- 206010002091 Anaesthesia Diseases 0.000 title abstract 2
- 230000037005 anaesthesia Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000003792 cranial nerve Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 210000000613 ear canal Anatomy 0.000 abstract 1
- 230000001815 facial effect Effects 0.000 abstract 1
- 210000000256 facial nerve Anatomy 0.000 abstract 1
- 210000001932 glossopharyngeal nerve Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000003901 trigeminal nerve Anatomy 0.000 abstract 1
- 210000001186 vagus nerve Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Métodos para tratar varias enfermedades, que comprenden la anestesia auricular de los nervios vago, facial, trigémino o glosofaríngeo o combinaciones de estos. Una composición farmacéutica se administra en un canal auditivo de un individuo que necesita el tratamiento; la composición incluye un analgésico y un anestésico. También se proporcionan composiciones útiles en los métodos divulgados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819023P | 2013-05-03 | 2013-05-03 | |
| PCT/US2014/036855 WO2014179814A1 (en) | 2013-05-03 | 2014-05-05 | Method of treating disease by auricular anesthesia of cranial nerves |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015015194A true MX2015015194A (es) | 2016-02-11 |
| MX381106B MX381106B (es) | 2025-03-04 |
Family
ID=51844020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015194A MX381106B (es) | 2013-05-03 | 2014-05-05 | Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales. |
| MX2018005625A MX390998B (es) | 2013-05-03 | 2016-11-02 | Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005625A MX390998B (es) | 2013-05-03 | 2016-11-02 | Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20140357686A1 (es) |
| EP (2) | EP2991620B1 (es) |
| JP (3) | JP6433985B2 (es) |
| KR (2) | KR102086709B1 (es) |
| CN (2) | CN105163718B (es) |
| AU (2) | AU2014262148B2 (es) |
| CA (2) | CA2910422C (es) |
| DK (1) | DK2991620T3 (es) |
| ES (1) | ES2823624T3 (es) |
| HK (1) | HK1212230A1 (es) |
| IL (2) | IL242339B (es) |
| MX (2) | MX381106B (es) |
| MY (2) | MY180310A (es) |
| RU (2) | RU2687249C2 (es) |
| SG (1) | SG11201508509XA (es) |
| WO (2) | WO2014179814A1 (es) |
| ZA (2) | ZA201508782B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105163718B (zh) * | 2013-05-03 | 2020-03-17 | 托马斯·M·克鲁斯 | 通过耳麻醉脑神经治疗疾病的方法 |
| EP3263103A4 (en) * | 2015-02-26 | 2018-03-14 | Limited Liability Company "konsortsium-pik" | Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using said composition |
| AU2017324262B2 (en) | 2016-09-07 | 2023-06-22 | Glia, Llc | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| US20220105052A1 (en) * | 2016-12-26 | 2022-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| CN107789621A (zh) * | 2017-12-15 | 2018-03-13 | 阜阳市平衡医疗保健器械有限公司 | 一种治疗头痛的药物及其配制方法 |
| US11607275B2 (en) * | 2019-05-20 | 2023-03-21 | Medtronic Ireland Manufacturing Unlimited Company | Selection of hypertensive patients for treatment with renal denervation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19524691A1 (de) * | 1995-07-06 | 1997-01-09 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen |
| RU2104056C1 (ru) * | 1995-07-10 | 1998-02-10 | Александр Александрович Ланцов | Способ лечения периферических поражений лицевого нерва |
| JPH1094613A (ja) * | 1996-08-02 | 1998-04-14 | Mieko Sato | 食欲調整用具 |
| US6093417A (en) * | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
| WO2000072835A2 (en) * | 1999-05-27 | 2000-12-07 | El Khoury George F | Topical application of muscarinic and opioid agents for treatment of tinnitus |
| DE10322497A1 (de) * | 2003-05-19 | 2004-12-09 | Liedtke, Rainer K., Dr. | Topisch pharmakologische Vorbeugung und Therapie der Hyperakusis |
| US8940321B2 (en) * | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
| US8755892B2 (en) * | 2007-05-16 | 2014-06-17 | Cardiac Pacemakers, Inc. | Systems for stimulating neural targets |
| WO2011019954A2 (en) * | 2009-08-13 | 2011-02-17 | Yehuda Ivri | Intracochlear drug delivery to the central nervous system |
| US20120252730A1 (en) * | 2009-09-03 | 2012-10-04 | University Of Chicago | Platelet aggregation inhibitors |
| EP2755546A4 (en) * | 2011-09-15 | 2015-08-12 | Yoseph Yaacobi | SYSTEMS AND METHOD FOR THE TREATMENT OF EARLIER DISEASES |
| CN105163718B (zh) * | 2013-05-03 | 2020-03-17 | 托马斯·M·克鲁斯 | 通过耳麻醉脑神经治疗疾病的方法 |
-
2014
- 2014-05-05 CN CN201480024269.1A patent/CN105163718B/zh active Active
- 2014-05-05 RU RU2015148757A patent/RU2687249C2/ru active
- 2014-05-05 US US14/270,238 patent/US20140357686A1/en not_active Abandoned
- 2014-05-05 SG SG11201508509XA patent/SG11201508509XA/en unknown
- 2014-05-05 MX MX2015015194A patent/MX381106B/es unknown
- 2014-05-05 MY MYPI2015002669A patent/MY180310A/en unknown
- 2014-05-05 WO PCT/US2014/036855 patent/WO2014179814A1/en active Application Filing
- 2014-05-05 HK HK16100269.6A patent/HK1212230A1/xx unknown
- 2014-05-05 DK DK14791131.7T patent/DK2991620T3/da active
- 2014-05-05 AU AU2014262148A patent/AU2014262148B2/en active Active
- 2014-05-05 JP JP2016512111A patent/JP6433985B2/ja active Active
- 2014-05-05 CA CA2910422A patent/CA2910422C/en active Active
- 2014-05-05 KR KR1020157033239A patent/KR102086709B1/ko active Active
- 2014-05-05 ES ES14791131T patent/ES2823624T3/es active Active
- 2014-05-05 EP EP14791131.7A patent/EP2991620B1/en active Active
-
2015
- 2015-10-29 IL IL242339A patent/IL242339B/en active IP Right Grant
- 2015-11-03 US US14/931,581 patent/US9968589B2/en active Active
- 2015-12-01 ZA ZA2015/08782A patent/ZA201508782B/en unknown
-
2016
- 2016-11-02 AU AU2016349784A patent/AU2016349784B2/en active Active
- 2016-11-02 MX MX2018005625A patent/MX390998B/es unknown
- 2016-11-02 JP JP2018543020A patent/JP2018536709A/ja active Pending
- 2016-11-02 CA CA3004160A patent/CA3004160C/en active Active
- 2016-11-02 RU RU2018118068A patent/RU2701548C1/ru active
- 2016-11-02 CN CN201680077107.3A patent/CN108430470A/zh active Pending
- 2016-11-02 MY MYPI2018701738A patent/MY196979A/en unknown
- 2016-11-02 WO PCT/US2016/060085 patent/WO2017079270A1/en active IP Right Grant
- 2016-11-02 EP EP16862858.4A patent/EP3370716A4/en active Pending
- 2016-11-02 KR KR1020187015606A patent/KR102796310B1/ko active Active
-
2018
- 2018-04-29 IL IL259019A patent/IL259019B/en active IP Right Grant
- 2018-05-14 US US15/978,742 patent/US11123284B2/en active Active
- 2018-05-25 ZA ZA2018/03483A patent/ZA201803483B/en unknown
-
2021
- 2021-09-20 US US17/479,780 patent/US20220387307A1/en not_active Abandoned
-
2022
- 2022-02-07 JP JP2022016897A patent/JP7512317B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| MX388693B (es) | Composiciones de nanoparticulas para terapia sostenida. | |
| CL2015003731A1 (es) | Inhibidores de bromodominios | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
| EA201690881A1 (ru) | Соединения-ингибиторы аутотаксина | |
| NZ750187A (en) | Pyridone amides as modulators of sodium channels | |
| MX2015015194A (es) | Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales. | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| ECSP12012354A (es) | Compuestos heterocíclicos, su preparación y su aplicación terapéutica | |
| EA201690880A1 (ru) | Тетрациклические ингибиторы аутотаксина | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| BR112016028316A2 (pt) | composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
| EA201590656A1 (ru) | Азаиндолины | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| MX369451B (es) | Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. |